Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

midostaurin

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

UK reaffirms NHS access to NICE-approved drugs

Health Secretary makes pledge on same day Future Forum recommendations on NHS reform accepted

- PMLiVE

Interview: Joseph Jimenez, Novartis

Novartis' CEO tells Linda Banks how investing in innovation and parallel development is helping to keep the company at the forefront

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links